Manufacturer record
Sayora Pharma Private Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Sayora Pharma Private Ltd (Haryana) was declared Not of Standard Quality in November 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: AP-120, Atropine Sulphate Ophthalmic Solution USP 1% (exp Nov 2026). CDTL, Mumbai (CDSCO lab) found it not of standard quality: The sample received does not conform to I.P. 2022 with respect to the test for Relatee substances. Listed in the November 2025 alert.
Records by type
1 record linked to Sayora Pharma Private Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Atropine Sulphate Ophthalmic Solution USP 1% | Batch AP-120Mfg Dec 2024 · Exp Nov 2026 | The sample received does not conform to I.P. 2022 with respect to the test for Relatee substances.Other | CDTL, MumbaiCDSCO lab | Nov 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.